Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroendocrine Tumors × Yttrium-90 × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Cholangiocarcinoma 2 Sarcoma 1 Recurrence 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Hepatocellular 1 Bile Duct Neoplasms 1

Interventions

lutetium Lu 177 dotatate 15 Everolimus 10 Temozolomide 9 Nivolumab 8 Capecitabine 7 pembrolizumab 6 cabozantinib 5 Sunitinib 5 lanreotide 4 gallium Ga 68 dotatate 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 lenvatinib 3 avelumab 3 Octreotide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Injections 3 Etoposide 3 Cyclophosphamide 3 Carboplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2 Specimen Handling 2 Positron Emission Tomography Computed Tomography 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04339036 2025-12-10

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡